To develop a fully bioactive humanized antibody from the chimeric rituximab for potential clinical applications using a relatively simpler and faster logical and bioinformatics approach. Methods: From bioinformatics data, mismatched mouse amino acids in variable light and heavy chain amphipathic regions were identified and substituted with those common to human antibody framework. Appropriate synthetic DNA sequences inserted into vectors were transfected into HEK293 cells to produce the humanized antibody. Results: Humanized antibodies showed specific binding to CD20 and greater cytotoxicity to cancer WIL2-NS cell proliferation than rituximab in vitro. Conclusion: A humanized version of rituximab with potential to be developed into a biobetter for treatment of B-cell disorders has been successfully generated using a logical and bioinformatics approach.
Immunotherapy using monoclonal antibodies (mAbs) is an important arsenal in the treatment of cancer. Most antibodies are first developed in mice. However, the use of mouse antibodies is limited by the fact that they produce an undesired human antimouse antibody response, which renders the treatment ineffective over time or even produce undesired side effects [1] . To overcome human anti-mouse antibody response, chimeric mAbs that predominantly carry the human antibody framework except for the variable region at the recognition sites were generated, such as rituximab, abciximab [2] , infliximab [3] , basiliximab [4] and cetuximab [5] . However, since the chimeric mAb still retains a considerable number of nonhuman amino acid sequences, the potential and risk of an immunogenic response is always a possibility. Additional substitutions of the amino acids with human sequences in the variable regions (humanization) have been done to even further reduce the i mmunogenic potential.
Several approaches have been made to humanize mouse mAbs. The most common method employed is the complementarity determining region (CDR) grafting method [6, 7] . CDR-grafting approach involves the transfer of the CDRs from a mouse antibody to the Fv frameworks of a human antibody. However, one of the continuously debated issues concerning CDRgrafted antibodies is the possible loss of binding ability after modifications have been made to framework that are critical for retaining the conformation of the CDRs and antigen-antibody interaction. Therefore laborious and time-consuming back-mutation of mouse residues that are critical for CDR loop conformation into human framework is required [8] . Modified grafting methods have reduced the number of amino acids that need to be grafted but the process is still Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach with retention of biological activity future science group
Research Article Khoo, Cheah & Chong laborious [9] . Other methods have been developed for producing humanized antibodies. Recently, genetically engineered mice [10] and phage display technology [11] have also been developed to produce fully human antibodies. Only one full immunogenicity data of Humira (adalimumab), a human mAb generated by CAT's phage display technology, are available. The repetitive treatment with Humira demonstrated immunogenicity in 12% of patients, classified as tolerable degree of immunogenicity [12] . No complete data comparing fully human antibodies with humanized mAbs for s pecific antigens are known at present.
In this paper, we describe the generation of a humanized version of the anti-CD20 chimeric mouse/ human IgG1-κ mAb, rituximab (brand name: MabThera ® ) using a logical bioinformatics approach in which selected mouse amino acids in the amphipathic areas of the variable regions were directly substituted with the most commonly found ones on the human variable framework [8] . The logical approach first identifies the vernier regions in the CDR regions which are critical in maintaining of epitope binding sites and must be remain unaltered; the amphipathic regions that are not critical can be further modified. Thus, only mismatched amino acids in the amphipathic regions are substituted: in theory this should reduce its immunogenicity without affecting binding activity. This approach is more predictive of the outcome in retaining immunological activity and bioactivity of the humanized mAb, and is easier and more direct and with present technology more cost effective to perform than the CDR-grafting method. We have previously successfully humanized a fully mouse mAb against the C2 antigen, a marker for colorectal cancer, by this method and showed that it retained full immunoreactivity after humanization [8] . Here, we describe the humanization of a chimeric mAb, rituximab, which carries the human constant region and a humanmouse variable region.
Rituximab was approved by US FDA in 1997 for the treatment of patients with relapsed/refractory lowgrade/follicular B-cell non-Hodgkin's lymphoma. Rituximab recognizes with high specificity the CD20 antigen expressed on the surface of both normal and malignant B-lymphocytes. With the binding of the Fab domain of rituximab to CD20, the Fc domain mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, which then induces apoptosis of B cells [13] . Direct induction of apoptosis following the binding of rituximab to CD20 has also been proposed and this might play a role in the depletion of B cells by triggering down-regulation of the anti-apoptotic molecules Bcl-2 and Bcl-xL, subsequently leading to sensitization for drug-induced apoptosis, translocation of CD20 into lipid rafts, caspase activation and poly (ADP-ribose) polymerase (PARP) cleavage [14] [15] [16] [17] . After depletion, a new population of healthy B cells can be obtained from stem cells and pre B cells.
Production of a humanized version of rituximab is desirable because although chimerization of mousederived mAb can diminish the possibility of inducing immunogenicity and drug resistance in patients, it still can generate undesirable anti-variable region responses [1] . It is well-established that rituximab is proven effective in the treatment of B-cell non-Hodgkin's lymphoma; however, 52% of patients with relapsed low-grade or follicular lymphoma showed unresponsiveness to a four-dose rituximab treatment program (innate resistance) [18] . Another study done for safety and efficacy of rituximab retreatment demonstrated that 60% of patients who had responded to prior rituximab therapy were not responsive to retreatment with the rituximab (acquired resistance) [19] . Recently, human antichimeric antibody (HACA) are frequently observed in autoimmune disease patients treated with rituximab as compared with lymphoma patients treated with rituximab [20] [21] [22] [23] [24] [25] . Several studies have showed a correlation between the presence of rituximab HACA and incomplete B-cell depletion in patients with systemic lupus erythematosus [20, 21] , serum sickness-like disorders in Sjogren's syndrome and immune thrombocytopenic purpura [22, 23] . In addition, poor clinical outcome and infusion adverse events were reported to be correlated with rituximab HACA in pemphigus patients [24] . Recently Lunardon and Payne described the first direct evidence for neutralizing effects of rituximab HACA in pemphigus vulgaris patients [25] . Based on Uchiyama, the neutralizing antibodies are induced during therapy and that the level of dosage and therapeutic periods increase the probability of inducing neutralizing antibodies [26] . This problem acts as a barrier to successful immunotherapy of B-cell disorders using rituximab. To increase anti-tumor activity and Fc-binding affinity on immune effector cells, new generations of anti-CD20 mAbs are being developed [27] [28] [29] . Humanized antibodies that contain sequences with even higher degree of similarity to the human antibody Fab framework in comparison to the chimeric version, are essential to o vercome the therapeutic difficulties.
The main purpose of this project is to demonstrate that a humanized version of rituximab with retention of biological and immunological activity could be generated using the logical and bioinformatics approach with potential for development into useful treatment and diagnostic tools. The immunogenicity of the humanized rituximab and full characterization of the humanized mAb and its applications will be the s ubject of continuing studies.
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Materials & methods

Synthesis of variable region of humanized anti-CD20hIgG using logical & bioinformatics approach
The sequences of chimeric IgG for light chain variable region (anti-CD20cIgG-V L ) and heavy chain variable region (anti-CD20cIgG-V H ) were first obtained from patent paper published by Anderson et al. [30] . By using the AMPHI (Center of Molecular Immunology, Havana, Cuba) and IgBLAST programs (www.ncbi. nlm.nih.gov/igblast), the mismatched mouse-human amino acid residues in the amphiphatic region of the chimeric antibody to be substituted were identified. The humanized gene sequences were then sent to First BASE Laboratories (Selangor, Malaysia) for DNA sequencing. Next, the humanized anti-CD20hIgG-V L and anti-CD20hIgG-V H genes were inserted into pFUSE2-CLIg-hk and pFUSE-CHIg-hG1 plasmids (InvivoGen, USA), respectively. Following ligation and transformation into Escherichia coli, the two expression vectors containing humanized anti-CD20hIgG-V L and anti-CD20hIgG-V H were purified and quantified.
Expression & production of humanized antiCD20hIgG mAb
Cotransfection of linearized pFUSE2-CLlg-hk and pFUSE-CHlg-hG1 plasmids coding the antiCD20hIgG-V L and anti-CD20hIgG-V H into adherent HEK293 cells (ATCC, VA, USA) was performed using X-tremeGENE HP DNA transfection reagent (Roche, Germany). Colorimetric ELISA specific for human IgG was performed to assay the culture supernatant for the presence of humanized anti-CD20hIgG.
Selection of high-producer clones using automated ClonePix FL technology CloneMedia-HEK (Molecular Devices, CA, USA) containing CloneDetect anti-human-FITC (Molecular Devices) was mixed with 2000 cells from the high-producing parental colonies and spread gently into single-well plates (Molecular Devices). Plates were incubated in a CO 2 incubator at 37°C, 5% CO 2 for 14 days. Using the ClonePix FL system (Molecular Devices), the single-well plates were individually imaged under white light and fluorescence light. The system software was programmed to identify and pick the best clones for culture expansion.
Purification of humanized anti-CD20hIgG
The culture supernatant was concentrated ten-times by Minim II tangential-flow filtration system (Pall Corporation, NY, USA) using a membrane with molecular weight cut-off of 30 kD (Sartorius Stedim, Germany). Then the mAbs were purified using a HiTrap Protein-A HP column (GE Healthcare, UK) on the AKTA Prime Plus system (GE Healthcare) with 20 mM phosphate-180 mM sodium chloride, pH 7.5, as binding buffer. Bound anti-CD20hIgG was then eluted using 0.1 M glycine-HCl, pH 3. All fractions containing high absorbance at 280 nm were collected, pooled and conditioned to pH7.
Characterization of humanized anti-CD20hIgG
SDS-PAGE
The Tris-HCl resolving gel consisting of 14% T (total acrylamide concentration) with a stacking gel of 5% T. BenchMark TM Protein Ladder (Invitrogen, CA, USA) was used as a molecular weight standard. Samples and rituximab (as reference standard) were electrophoresed under denaturing conditions. The protein bands were visualized using both Silver Staining and Coomassie Blue dye.
Western blot
Anti-CD20hIgG was first separated by SDS-PAGE and transferred onto Hybond polyvinylidene difluoride (PVDF) blotting membrane (GE Healthcare, UK). The membrane was then incubated with 1:1000 dilution of anti-human rabbit IgG (Sigma-Aldrich, MO, USA) for 2 h, followed by 1:30,000 dilution of anti-rabbit goat IgG, conjugated to alkaline phosphatase (Sigma-Aldrich) for 1 h. Finally, membrane was incubated in BCIP/NBT substrate (Sigma-Aldrich) for 15-20 min. Dual Color Precision Plus protein standard (Bio-Rad, CA, USA) was used as molecular weight marker.
Cell culture CD20-expressing human B-lymphoblastoid cell line WIL2-NS (ATCC) was used to test the immunoreactivity and biological activity of the mAb. Cells were expanded and maintained in RPMI 1640 (Biochrom, Germany) supplemented with 2 mM L-glutamine (Sigma-Aldrich) and 10% fetal bovine serum (FBS; Biochrom, Germany).
Immunofluorescence cell-binding assay
The cell-binding assay was carried out using WIL2-NS cells (as described by Hong et al. with modifications [31] ). Cells were seeded at 300,000 cells/well into a poly-Dlysine microplate (Thermo Fisher Scientific, NY, USA) and fixed with 4% formaldehyde (Sigma-Aldrich). After washing, rituximab reference standard (10 μg/ ml), humanized anti-CD20hIgG (10 μg/ml), assay buffer (1× phosphate-buffered saline [PBS] containing 1% FBS) and Pierce ® Mouse IgG, whole molecule (Thermo Fisher Scientific) were added. F ollowing 45 min of incubation at 2-8°C, bound anti-CD20hIgG was detected future science group Research Article Khoo, Cheah & Chong by adding 100 μl of anti-human IgG (Fc specific)-fluorescein isothiocyanate (FITC) conjugate (SigmaAldrich) and incubated at 2-8°C for another 45 min. Once incubation was complete, cells were washed and examined under a fluorescence microscope. The CD20-deficient CCRF-HSB cells (ATCC) were also included in the assays to monitor non-specific binding.
Cell-based ELISA
A total of 25,000 WIL2-NS cells/well were seeded into a poly-D-lysine microplate. After fixing with 0.05% glutaraldehyde, and blocking in 1× PBS containing 3% BSA and 0.02% Tween-20, 100 μl of 15.6-1000 ng/ml humanized anti-CD20hIgG (HUMAX-2:1-A1-A4, A7 and A3) or equivalent concentrations of rituximab were added and incubated at 37°C for 2 h, followed by addition of 20 μl of 1:1000 dilution of anti-human goat IgG, peroxidase conjugate (Sigma-Aldrich) and incubated for another 2 h at 37°C. For the dilutions of humanized mAb, rituximab and conjugate, 1× PBS containing 0.08% BSA was used as a diluent. After incubation with 100 μl ABTS working solution, the absorbance was measured at 405 nm. Quantitative analysis of rituximab and humanized mAb samples were performed using a Four Parameter Logistic (4PL) curve-fitting program. At the midpoint absorbance (mid-OD) of the rituximab standard curve, the corresponding concentrations of rituximab and humanized mAbs were determined, and the relative binding affinity was calculated.
Cell proliferation assay using WIL2-NS cells
This assay compares the bioactivity of humanized anti-CD20hIgG to the rituximab by their ability to inhibit the proliferation of WIL2-NS cells in vitro in combination with chemotherapy drug, cyclophosphamide (Acros Organics, Belgium). WIL2-NS cells were seeded at a concentration of 200,000 cells/well in RPMI 1640 medium into a poly-D-lysine microplate. Rituximab and humanized anti-CD20hIgG was diluted in RPMI 1640 medium to appropriate concentrations. Then, 100 μl of different concentrations (2-5000 ng/ml) of rituximab or humanized anti-CD20hIgG, together with 40 mM cyclophosphamide were added to each well and cells were incubated at 37°C, 5% CO 2 for 44-48 h. Next, a mixture of 40 μl of CellTiter 96 ® aqueous MTS reagent (Promega, WI, USA) and PMS (Sigma-Aldrich) was added, and incubation continued for 4 h at 37°C, 5% CO 2 . Dehydrogenase enzymes in living cells convert the tetrazolium component of the CellTiter 96 ® reagent into a soluble formazan product which was measured at 490 nm. Data were fitted into a 4PL curve using SigmaPlot Software (Systat Software, CA, USA) and the IC50 of anti-CD20hIgG and rituximab were determined. Measurements were performed in triplicate and data were expressed as mean ± SD. Statistical analysis to compare the difference in response at the same dosage of anti-CD20hIgG and rituximab was done by two-tail Student's t-test [32] .
Results
Development of humanized anti-CD20 mAbs
From the output of AMPHI analysis, only one midpoint of amphipathic block was identified in chimeric anti-CD20cIgG-V L . Since five amino acid residues before and after the mid-point of amphipathic block were also considered amphipathic [33] , the amphipathic block was expanded from Residues 107-116 to Residues 102-121. As for the chimeric antiCD20cIgG-V H , seven mid-points of amphipathic blocks were identified, Residues 9-22, 14-27, 22-33, 27-40, 58-74, 95-107 and 126-138 ( Figure 1A) .
Using IgBLAST program, the chimeric Fab sequence were aligned against the database of human immunoglobulin (Fab) genes. The mismatched amino acids of the chimeric Fab sequence that differed from those in the human gene were identified and substituted by appropriate individual amino acids that occurred with the highest homology (>90%) in the human Fab frameworks ( Figure 1B) .
By this method, one residue in anti-CD20cIgG-V L and six residues in anti-CD20cIgG-V H that differed from their respective homologous human sequences, were identified in the amphipathic regions. Hence, for humanization, substitution was proposed on Residue 82 in anti-CD20cIgG-V L , and on Residues 5, 7, 20, 40, 43 and 87 in anti-CD20cIgG-V H , as shown in Figure 1B . The codon that required the least number of nucleotide substitutions was chosen as 'substitute'.
Selection of high-producer clones using automated ClonePix FL technology By Day 14, antibody-secreting colonies could be visualized under white light and fluorescence light. Only clones secreting anti-CD20hIgG displayed localized fluorescence light. A dot-plot of exterior fluorescence intensity against colony size (mm 2 ) was constructed. This ranking plot enabled us to filter through a large number of clones and only select the few that met our pre-selection criterion of >1000 fluorescence unit. A total of 1429 colonies were analyzed and 22 clones with highest fluorescence intensity were picked. The ELISA results identified three high-producing colonies coded as A4, A7 and A3 which were expanded.
Purification of anti-CD20hIgG antibodies
The anti-CD20hIgG antibody eluted as a single peak when it was displaced from the HiTrap Protein-A HP future science group Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach Research Article column. The fractions with high anti-CD20hIgG concentration were pooled and the purity was assessed by gel electrophoresis.
SDS-PAGE
As shown in Figure 2A , rituximab and antiCD20hIgG of affinity chromatography (AC) eluate (A4, A7 and A3) can be visualized as two bands at . However, some other extra bands were also observed and further purification will be necessary to remove these possible impurities. The spent culture media and ultra-filtration/diafiltration retentate had multiple bands as expected because of the presence of medium components and FBS.
Western blot
Western blotting of the anti-CD20hIgG-A4 of AC eluate resulted in two bands near 25 and 50 kD on the PVDF membrane, which were comparable to the rituximab and corresponded to the molecular weights of the heavy and light chains of human IgG (Figure 2A ).
Immunoreactivity of humanized anti-CD20hIgG
Immunofluorescene cell-binding assay was performed using CD20-expressing WIL2-NS cells. High fluorescence images were observed in wells where cells were exposed to anti-CD20hIgG-A4 and rituximab, whereas no or undetected fluorescence signal could be found in wells where assay buffer and unrelated mouse IgG (negative controls) were used ( Figure 2B ). When CD20-deficient CCRF-HSB cells were incubated with anti-CD20hIgG-A4 and rituximab, no fluorescence was observed.
Cell-based ELISA
Cell-based ELISA was used for measuring the binding activity of the humanized anti-CD20hIgG-A1-A4, A7 and A3 to CD20-expressing WIL2-NS cell line. According to Hong et al., cell-based ELISA using live suspension WIL2 cells is quantitative and reproducible [31] . The relative binding affinity of rituximab to the anti-CD20hIgG-A4, A7 and A3 were 1.19, 0.54 and 0.29, respectively, while anti-CD20hIgG-A4 demonstrated comparable binding affinity with that of rituximab ( Figure 3A ).
Cell proliferation assay using WIL2-NS cells
The cytotoxicity effect of the humanized antiCD20hIgG-A4 mAb was evaluated using cell proliferation 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Incubation of the cells with increasing levels of anti-CD20hIgG-A4 and a fixed dose of cyclophosphamide ( Figure 3B ) resulted in significant and dose-dependent growth inhibition on WIL2-NS cells, comparable to rituximab. In fact the inhibitory curve for anti-CD20hIgG-A4 shifted to the left and was steeper than that of rituximab. This suggests that anti-CD20hIgG-A4 inhibited cell proliferation more effectively than rituximab from doses of between 4.9 and 78.1 ng/ml (p < 0.05). The IC50 of anti-CD20hIgG-A4 (7.0 ng/ml) was significantly lower than rituximab (26.3 ng/ml) suggesting that Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach Research Article anti-CD20hIgG-A4 may be more effective in inhibiting WIL2-NS cell growth.
Discussion
Rituximab is widely used for the treatment of B-cell disorders and has been increasingly used in c ombination with other standard cancer therapies such as chemotherapy and radiation, with promising results. The response rate for rituximab as the single agent for low-grade, B-cell lymphomas was reported to be over 50% [18] , and 95% when combined with standard chemotherapy drugs (cyclophosphamide, Research Article Khoo, Cheah & Chong doxorubicin, vincristine and prednisolone) [34] . However, studies have shown that in some patients, increasing and prolonged use of rituximab gives rise to resistance to treatment response [18, 19] . One of the reasons for this may be due to 'self' antibody response, also known as HACA response to rituximab [20] [21] [22] [23] [24] [25] [26] . To the immunologist, this HACA phenomenon is readily anticipated, since rituximab in its genetic construct still carries the mouse sequence in the antibody's variable regions, giving rise to human antibodies against it, and adversely affecting its efficacy. Hypothetically, this HACA issue can be overcome by further humanizing the chimeric mAb. In this study, we describe the modification of rituximab to generate the 'humanized' anti-CD20hIgG antibody, based on logical and bioinformatics approach, without compromising its unique biological and immunological characteristics.
The humanization was done by logical approach employing AMPHI software and bioinformatics IgBLAST program to determine the mismatched amino acids in the chimeric version to be replaced. The mouse amino acids were substituted with the blueprint genes of specific amino acids which bear the highest degree of homology to the human antibody's amino acid framework. Amino acid residues in the CDR regions, which are considered vital for antibody binding to antigen were not tampered with. Using the AMPHI program, vernier zones and amphipathic residues of the anti-CD20cIgG variable regions were identified [35] . This algorithm is based on the amphipathic helix model in which antigenic sites are postulated to be helices with one face predominantly polar and the opposite face predominantly apolar [36] . Vernier zone residues in the β-sheet framework regions have been known to critically affect antigen binding by directly contacting the antigen, affecting CDR loop conformation and/or influencing packing interactions between β-sheet strands; for these reasons, they were left unchanged [37] . The amphipathic residues are not required for antigen recognition and so were chosen for the humanization process. Using these humanized gene sequences, we then constructed the expression profile for the plasmids for subsequent t ransfection into human HEK293 cells.
Glycosylation has a significant influence on the functional and physical properties of recombinant antibody, and is one of the most important critical quality aspects for safety and optimal efficacy of a biologics drug [38] . Cells from non-primate animals such as Chinese hamster ovary (CHO) in which the original rituximab have been generated found to produce glycosylation patterns that are different from human cells [39] . In this study, the humanized rituximab are generated using human cells, with the advantage that they are able to produce an authentically human glycan profile [40] , without glycosylated structures of Galα1,3-Gal residues (α-Gal) and N-glycolylneuraminic acid (Neu5Gc) epitopes that are antigenic in humans [41] . The humanized anti-CD20hIgG mAb which retains the immunoreactivity and bioactivity of the original rituximab indicates that any alterations in g lycosylation patterns had no deleterious effect.
A protein-A column was used to purify the humanized anti-CD20hIgG mAb, but gel electrophoresis analysis indicates that the antibody eluate may still contain some impurities of the same molecular weight as the heavy and light chains of the antibody. However, western blotting of the transferred proteins from the AC eluate showed only two distinct bands at the heavy chain and light chain molecular weights, similar to the rituximab reference standard. This result indicates the presence of a single species of humanized antibody. The extra bands from the AC eluate were not reactive to the anti-human rabbit IgG: this implies that the AC eluate may contain bovine IgG that originated from FBS mixed in the cell culture growth media. These bovine antibodies were probably co-eluted with the humanized anti-CD20hIgG. This issue can be easily resolved when the antibody-producing cells are adapted into serum-free media.
One of the major issues concerning humanized antibodies is the possible loss of binding ability after the humanization process. Our results show that we have successfully generated a humanized mAb (antiCD20hIgG-A4) which retains at least the same degree of immunoreactivity and probably greater biological activity as that of rituximab. The immunofluorescence cell-binding studies demonstrated directly that the humanized mAb produced retained its ability to bind to the CD20 antigen expressed on WIL2-NS cells. The observed binding depicted by fluorescence signal images of anti-CD20hIgG-A4 to CD20-expressing WIL2-NS cells but not to CCRF-HSB cells which are CD20 deficient, indicates that binding of anti-CD20hIgG was specific, which is to be expected because no changes were made in the vernier zones, which is important for antigen recognition [42] . The cell-based ELISA showed that the relative binding affinity between rituximab and its humanized version was about the same because the estimated relative binding affinity was 1.19. This suggests that substitution of the amino acids at the amhipathic regions that was decided upon from bioinformatics data did not drastically alter immunoreactivity.
One of the key characteristics of rituximab is its cytotoxicity toward malignant CD20-expressing cells in vitro and in vivo, especially in combination with cytotoxic chemotherapy drug, cyclophosphamide [34, 43] . Rituximab binds to the target CD20 molecule via the future science group Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach Research Article chimeric Fab, while the Fc domain of the antibody reacts with human effector function to kill the targeted cells. A recent study by Kumar et al. provides another possible mode of action of rituximab, in other words, apoptosis in in vitro against CD20-expressing Raji cells [44] . Our studies showed that the humanized antiCD20hIgG-A4 possessed considerable cytotoxic effect toward WIL2-NS proliferation profile, which matched and even surpassed that of rituximab when cells were exposed to increasing doses of anti-CD20hIgG-A4 and rituximab in the presence of cyclophosphamide. This shows that anti-CD20hIgG-A4 effectiveness is comparable and even exceeds that of rituximab in inhibiting the proliferation of the WIL2-NS cancer cells in vitro.
However, it is important to note that these are in vitro studies, and much extensive studies should be done to evaluate its potential to be developed as a therapeutic agent. Its efficacy in vivo will need to be tested in animal studies, for example, with immunodeficient mice carrying xenografts of induced CD20 positive tumors. The potential immuno-antigenicity of the humanized mAb will have to be assessed using non-human primates, which will require extensive ethics panel consideration and expense. The mechanism of action of the humanized antibody need to be compared with that of rituximab, although they should be essentially the same since humanized antibody is derived from the parent rituximab molecule and the Fc fragment is identical.
In summary, in this study we have shown that we have successfully humanized a mAb with retention of immunoreactivity and bioactivity of the original molecule using the logical and bioinformatics method. This procedure algorithmically 'mapped-out' the amino acids in the amphipathic frameworks, which are potentially antigenic and can be humanized [35] , while amino acids in the CDR and vernier zones which are important for antigen recognition were also algorithmically identified and judiciously preserved.
Using these remapped gene sequence information, generation of humanized mAbs of equal, if not greater, efficiency can be achieved. This is the first humanized mAb derived from a chimeric mAb, rituximab, by bioinformatics and logical method that has been shown to retain both bioactivity and immunoactivity. We had similarly humanized a mouse mAb against C2 antigen, a marker for colon cancer, without affecting immunoactivity [8] . The results show that this is a viable and simpler technique to antibody humanization than the more commonly used CDR-grafting, which is prone to errors in amino acids substitution as well as being laborious and time consuming [8] . This reinforces the evidence pointing to the advantage of using the logical method in positively predicting the amphiphatic regions and quickly designing humanized constructs for the mouse or chimeric mAb of interest. Whether the further substitution of these human amino acids will in fact reduce its immunogenicity in humans and primates need further study.
Conclusion
We have successfully generated a humanized version (anti-CD20hIgG-A4) of the chimeric anti-CD20 antibody, rituximab, with comparable, if not better inhibitory effect against the in vitro proliferation of WIL2-NS cells than the original chimeric version. The humanization process was achieved using deduction through the analysis of logical and bioinformatics algorithm. The information presented provide preliminary clue that upgrading chimeric antibody into a humanized version could improve the overall efficacy of the biologics for therapeutic purposes. Hence, it is a first step into creating biobetters which are defined as 'enhanced versions of biosimilars'. This work further demonstrates the usefulness of the logical and bioinformatics methods not just as a humanization tool but also as an enhancement tool for biologics generation.
Summary points
• Humanization of rituximab process was achieved using logical and bioinformatics approach and seven mismatched amino acids of the chimeric Fab sequence were substituted by appropriate individual amino acids that occurred with the highest homology (>90%) in the human Fab frameworks.
• Selection, isolation and expansion of high-producer HEK293 clones using automated ClonePix FL technology were achieved within 1-month period.
• Of the various antibodies generated, anti-CD20hIgG-A4 demonstrated the highest relative binding affinity in cell-based ELISA.
• Using immunofluorescence cell-binding assay, the humanized rituximab (anti-CD20hIgG-A4) was shown to retain specific binding to CD20 antigen expressed by the WIL2-NS cells.
• In vitro studies showed that cytotoxic effects of humanized anti-CD20hIgG-A4 exceeds that of rituximab in inhibiting the proliferation of the WIL2-NS cancer cells.
• Humanized anti-CD20hIgG was biologically and immunologically reactive as no changes were made in the complementarity determining regions as well as in the vernier zones, which are both important for antigen recognition. No writing assistance was utilized in the production of this manuscript.
